Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 15/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25722346 | 0.88 | NAMPT (0.58) | NAMPTNPC1RAB9A | |
| SCHEMBL25725290 | 0.87 | NAMPT (0.57) | NAMPTEGFRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25722352 | 0.85 | NPC1 (0.59) | NAMPTEGFRNPC1RAB9A | |
| SCHEMBL25722339 | 0.85 | NAMPT (0.57) | NAMPTEGFRCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25725288 | 0.84 | NAMPT (0.54) | NAMPTNPC1RAB9A | |
| SCHEMBL25725979 | 0.84 | NAMPT (0.59) | NAMPTNPC1RAB9A | |
| SCHEMBL25723176 | 0.82 | NAMPT (0.50) | NAMPTNPC1RAB9A | |
| SCHEMBL25725946 | 0.79 | NAMPT (0.50) | NAMPTNPC1RAB9A | |
| SCHEMBL25724174 | 0.79 | NAMPT (0.50) | NAMPTNPC1RAB9A | |
| SCHEMBL25724197 | 0.78 | NPC1 (0.51) | EGFRMEN1KMT2ATP53NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202980-A1 | N-(2-Aminophenyl)-Prop-2-Enamide Derivatives, and Uses Thereof in the Treatment of Cancer | SALL4, GLI2, GLI1 | NAMPT 1176/4885EGFR 261/4885CYP1A2 3220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.